$68.48
3.96%
Downside
Day's Volatility :6.52%
Upside
2.67%
86.36%
Downside
52 Weeks Volatility :90.6%
Upside
31.11%
Period | Viking Therapeutics, Inc. | |
---|---|---|
3 Months | 17.28% | |
6 Months | -5.35% | |
1 Year | 589.63% | |
3 Years | 997.44% |
Market Capitalization | 7.3B |
Book Value | $8.18 |
Earnings Per Share (EPS) | -0.94 |
PEG Ratio | -0.03 |
Wall Street Target Price | 117.36 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -12.68% |
Return On Equity TTM | -15.5% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
Diluted Eps TTM | -0.94 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.98 |
EPS Estimate Next Year | -1.51 |
EPS Estimate Current Quarter | -0.25 |
EPS Estimate Next Quarter | -0.28 |
What analysts predicted
Upside of 71.38%
Sell
Neutral
Buy
Viking Therapeutics, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
Viking Therapeutics, Inc. | 4.01% | -5.35% | 589.63% | 997.44% | 789.35% |
Regeneron Pharmaceuticals, Inc. | -18.44% | -15.2% | 3.98% | 32.2% | 140.62% |
Biontech Se | -8.2% | 19.33% | 12.98% | -53.1% | 460.49% |
Alnylam Pharmaceuticals, Inc. | -2.42% | 85.09% | 68.13% | 60.32% | 200.09% |
Vertex Pharmaceuticals Incorporated | 7.27% | 20.19% | 36.37% | 178.01% | 155.94% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
Viking Therapeutics, Inc. | NA | NA | -0.03 | -0.98 | -0.15 | -0.13 | NA | 8.18 |
Regeneron Pharmaceuticals, Inc. | 20.41 | 20.41 | 1.2 | 44.89 | 0.17 | 0.07 | NA | 272.04 |
Biontech Se | 160.8 | NA | 0.04 | -3.1 | -0.02 | -0.01 | NA | 79.73 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -1.87 | -15.01 | -0.03 | NA | 0.25 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 1.27 | 0.19 | -0.03 | 0.13 | NA | 60.66 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
Viking Therapeutics, Inc. | Buy | $7.3B | 789.35% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $90.6B | 140.62% | 20.41 | 33.61% |
Biontech Se | Buy | $25.9B | 460.49% | 160.8 | -15.36% |
Alnylam Pharmaceuticals, Inc. | Buy | $35.1B | 200.09% | NA | -15.86% |
Vertex Pharmaceuticals Incorporated | Buy | $128.9B | 155.94% | 32.84 | -4.51% |
FMR Inc
Vanguard Group Inc
BlackRock Inc
State Street Corp
JPMorgan Chase & Co
Morgan Stanley - Brokerage Accounts
Viking Therapeutics, Inc.’s price-to-earnings ratio stands at None
Read Morenovel therapeutics for metabolic and endocrine disorders.
Organization | Viking Therapeutics, Inc. |
Employees | 30 |
CEO | Dr. Brian Lian Ph.D. |
Industry | Health Technology |